

## Healionics Q4 2023 Update

In Q4 of 2023, Healionics continued to follow patients in our ongoing *STARgraft* clinical study, saw the first public presentation of study results at a major clinical conference, oversubscribed our funding round, and received additional corporate recognition.

### Financial Snapshot

12/31/2023 Cash Balance: \$5,265k

Income in Q4:

Interest income + iSTAR royalty payment: \$51k

Operating Expenses in Q4: \$672k

### STARgraft Update

Our *STARgraft* vascular graft (synthetic blood vessel) is intended to provide a safer and more reliable means to access the bloodstream for dialysis in patients with kidney failure.

Our ongoing human study continues to show excellent results, now at 11 months median duration of active implants. Among the 12 patients implanted with our current version of *STARgraft*, there have been no device-related infections, occlusions, or interventions performed to prevent occlusion. These results compare favorably with on-market grafts, for which historical literature indicates 43% have typically occluded or required intervention to prevent occlusion and 9% have developed infections by this timepoint.

We are continuing periodic patient follow-up exams and intend to file an initial 510(k) for FDA clearance within the next few months.

### Presentation at a Major Clinical Conference

Interim results of our current human study were presented in October at the [Controversies in Dialysis Access](#) conference by Dr. John Ross, who co-founded the Vascular Access Society of Americas and is likely the world's most experienced vascular access surgeon. ([video here](#))

### Financing Round

Our preferred equity round is now oversubscribed with \$4.5M raised to date (vs. initial \$3M target) and final closing is expected later this month. These funds will support our efforts to reach FDA clearance and market launch. Please contact me if you are interested in participating and are an accredited investor.

### Intellectual Property

The European Patent Office (EPO) allowed our patent on a corrugated form of *STAR* biointerface that may be useful in a future iteration of *STARgraft* as well as a needle-free dialysis access port and other percutaneous (through-the-skin) devices. The EPO also allowed our patent on the potential use of *STAR* material to treat age-related macular degeneration. We now have a total of 36 patents issued or pending: 8 issued U.S., 23 issued or allowed internationally, and 5 pending in all countries.

### Company Recognition

Healionics was honored as a featured presenter at the renowned [Future in Review](#) conference and at the [Best of Keiretsu Forum](#) Investment Showcase.

### iSTAR Medical

Our spinout company iSTAR completed its second full year of commercial rollout in Europe and has now implanted [over 2,500 patients](#) with its *STAR* biomaterial-based MINInject glaucoma device. iSTAR is also continuing to enroll patients in its U.S. PMA clinical trial.

Mike Connolly

CEO

[Healionics Corporation](#)